GeneNews Ltd.

GeneNews Ltd.

GeneNews Ltd.

Overview
Date Founded

1998

Headquarters

Building 2,2 East Beaver Creek Road,Richmond Hill, ON L4B 2N3

Type of Company

Public

Employees (Worldwide)

26

Industries

Medical Products & Equipment
IT Consulting & Services
Hospitals & Patient Services
Commercial Scientific Research
Medical Support Services
Biotechnology

Company Description

GeneNews Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Markham, Canada.

In The News
Subscribe now to see full news coverage
Executives & Employees

Executive Chairman of the Board & Chief Executive Officer

Chief Financial Officer

Subscribe now to see full list of current and former executives
Board of Directors

Executive Chairman of the Board & Chief Executive Officer at GeneNews Ltd.

Chief Executive Officer at Breakwater Resources Ltd.

Founder & Chief Executive Officer at Locus Analytics

Co-Founder at JTS Ventures, Inc.

Co-Founder at Drawbridge Health, Inc.

Chief Financial Officer at GeneNews Ltd.

Subscribe now to see full list of current and former board members
Paths to GeneNews Ltd.
Potential Connections via
Relationship Science
You
GeneNews Ltd.
Recent Transactions
Details Hidden

GeneNews Ltd. raised money in a private placement transaction

Details Hidden

GeneNews Ltd. raised money in a private placement transaction

Details Hidden

GeneNews Ltd., GeneNews USA, Inc. purchase Innovative Diagnostic Laboratory LLP from Cobalt Healthcare Consultants, Inc.

Subscribe now to see full list of recent transations
Clients

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Subscribe now to see clients for over 2.5 million organizations
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$13.8M
Total Enterprise Value
$24.2M
Earnings Per Share
$-0.12
Revenue
$1.4M
Net Profit
$-7.83M
EBITDA
$-5.16M
EBITDAMargin
-369.69%
Total Debt
$4.05M
Total Equity
$-6.34M
Enterprise Value Sales
17.3x
TEVNet Income
-3.09x
Debt TEV
0.17x
Three Year Compounded Annual Growth Rate Of Revenue
119.47%
Five Year Compounded Annual Growth Rate Of Revenue
69.17%
Subscribe now to see full financial details
Non-Profit Donations & Grants
Subscribe now to see non-profit donations & grants for over 2.5 million organizations
Suppliers
Sphingotec GmbH Biotechnology | Hennigsdorf, BB

sphingotec GmbH is a private company headquartered in Hennigsdorf,, that develops method for prediction, prevention, intervention of cancer, cardiovascular disease and kidney function. The firm was founded by Andreas Bergmann. The company's website shows the following as a description of the firm: The bio technology company sphingotec GmbH, headquartered in Hennigsdorf, Germany, was founded in 2002. sphingotec aims to reduce or eliminate the risk of serious diseases such as cancer, cardiovascular diseases, and kidney conditions. The process starts before the disease has actually developed: using biomarkers to indicate susceptibility for a specific disease provides healthy individuals with the knowledge that they are at risk. What makes the approach so special is that the biomarkers also create a starting point for preventative strategies at the same time, as evidence-based recommendations on how to reduce risks are always an integral part of the complete concept.

Danaher Corporation Medical Support Services | Washington, DC

Danaher Corp. operates as a medical company, which designs, manufactures, and markets healthcare, environmental, and industrial equipment. It operates through the following segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research and clinical tools that scientists use to study cells and cell components in order to understand the causes of diseases; identify new therapies; and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as provide dental consumables, equipment, and services. The Environmental & Applied Solution segment engages in the development and manufacture of equipment, consumables, and software for various printing, marking, coding, design, and color management applications on consumer and industrial products. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Oncimmune Holdings Plc Biotechnology | Nottinghamshire, NG

Oncimmune Holdings Plc is an early cancer detection company that engages in the development and commercialization of its proprietary EarlyCDT platform technology. It has pioneer the development of tests based on the presence in the blood of autoantibody against specific tumor associated antigens that have the potential to detect cancer up to four years earlier than other methods of cancer detection, such as a chest X-ray, Spiral Computed Tomography or emerging technologies that do not benefit from the amplification of signal that occurs with the immune system, and can be applied to a very wide range of solid tumor types. The company was founded on October 9, 2015 and is headquartered in Nottinghamshire, the United Kingdom.

Subscribe now to see 1 more suppliers
Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company operates through the following business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. Its baby care franchise includes the JOHNSON'S Baby line of products. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines. The Medical Devices segment includes products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. It include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

OPKO Health, Inc. Pharmaceuticals - Wilmington, DE

OPKO Health, Inc. is a diversified healthcare company. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Genomic Health, Inc. Medical Support Services - Redwood City, CA

Genomic Health, a global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.